Project Grant R01HL188423
Award Date 8/15/26
Completion Date 5/31/30
Dollars Obligated $777K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Chapel Hill, NC 27599, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded the University of North Carolina at Chapel Hill $750,330 on July 10, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate MUC5AC structure, function, interactome, and its role in airway obstruction. The research addresses the molecular mechanisms by which MUC5AC, an airway mucin, contributes to chronic obstructive pulmonary disease and asthma pathogenesis. The project will define MUC5AC's unique macromolecular...
- The National Heart, Lung, and Blood Institute awarded $777,498 to the University of North Carolina at Chapel Hill on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct research on multiscale integration of mucin secretion and ion transport rates in asthmatic mucus plug formation and persistence. The research tests the applicability of a biophysical paradigm called the "two-gel" paradigm to asthma pathogenesis, examining whether asthma mucus...
- The National Heart, Lung, and Blood Institute awarded Duke University $215,504 under the Cardiovascular Diseases Research program (CFDA 93.837) on September 12, 2025, to fund research on epithelial cell-mediated fibroblast activation through CTHRC1-TGFB signaling in fibrotic lung diseases. The research investigates mechanisms of fibroblast activation in bronchiolitis obliterans and idiopathic pulmonary fibrosis. Aim 1 evaluates airway epithelial cell-fibroblast interactions contributing to...
- The National Heart, Lung, and Blood Institute awarded The University of Iowa $599,466 on August 19, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to fund research examining the cellular and molecular mechanisms driving submucosal gland hypertrophy in chronic lung diseases including asthma, COPD, and cystic fibrosis. The funded research will identify fundamental pathways responsible for pathological gland enlargement by defining key cell-cell interactions and signaling...
- Summary of Federal Cooperative Agreement Award The National Heart, Lung, and Blood Institute (NHLBI) awarded a Cooperative Agreement valued at $609,683.00 to the University of North Carolina at Chapel Hill, effective September 1, 2025 through May 31, 2030, under the Cardiovascular Diseases Research program (CFDA 93.837). The award establishes the Rare Bronchiectatic Diseases Consortium (RBDC) to investigate bronchiectasis (BE)—a severe pulmonary complication affecting four rare bronchiectatic...
- The National Heart, Lung, and Blood Institute awarded the Trustees of Boston University $712,630 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate functional heterogeneity of alveoli and early responses to airborne agents. The recipient will develop and apply the Crystal Ribcage, a novel intravital imaging platform, to visualize real-time, high-resolution dynamics of the intact, ventilating lung. The research will define the anatomy, physiology,...
- The National Heart, Lung, and Blood Institute awarded Brigham & Women's Hospital Inc. $894,314 on July 5, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop improved prediction and mechanistic understanding of chronic obstructive pulmonary disease exacerbations by integrating multi-trait genetics, proteomics, and deep learning methods. The research comprises three specific aims. In Aim 1, the recipient will develop a multi-trait polygenic risk score integrating...
- The National Heart, Lung, and Blood Institute awarded The Washington University $1.902 million on June 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to define and correct immune-epithelial pathways underlying chronic muco-obstructive lung disease triggered by viral infection, allergen, smoke, or pollution exposure. The research identifies and characterizes a distinct subset of basal epithelial stem cells (basal-ESCs) that drive muco-obstructive disease phenotypes...
- The National Institutes of Health National Heart, Lung, and Blood Institute awarded National Jewish Health $249,000 on July 24, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate rare airway cell function in post-viral chronic inflammation. The research examines the role of microfold (M) cells in the post-influenza lung, particularly their contribution to secondary bacterial infection susceptibility and host protection. Using single-nucleus transcriptomic and...
- The National Heart, Lung, and Blood Institute awarded The Trustees Of The University Of Pennsylvania $1,624,110 on June 25, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate mechanisms of lung repair and regeneration following acute injury. The project examines dysplastic versus euplastic repair pathways in lung tissue. The research addresses how basal stem cells migrate into the alveolar niche after injury, displacing AT2 progenitor cells and creating an...